Los Angeles Syndicate of Technology Announces its Portfolio Company, Sanguine BioSciences, Inc. Makes Major Appointment to Scientific Advisory Board
SANTA MONICA, Calif., April 10, 2012 /PRNewswire/ — Los Angeles Syndicate of Technology, Inc. (OTCQB: LAST), a publicly-traded venture fund and technology incubator, is pleased to announce that its portfolio company, Sanguine BioSciences, Inc. (“Sanguine”), has appointed Dr. Timothy J. Triche, MD, PhD to Sanguine’s Scientific Advisory Board. Sanguine BioSciences, Inc., an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines, was developed in LAST’s technology incubator.
“We are pleased to announce Professor Triche’s appointment to our Scientific Advisory Board,” said Brian Neman, Sanguine’s Chairman and Chief Executive Officer. “Dr. Triche has been a leader in genomic and biomarker research for decades, and provides the company with valuable strategic insight as the company is poised to begin digitizing biological and clinical data within its bio-repository.”
Professor Timothy J. Triche, of the Center for Personalized Medicine (CPM) at Children’s Hospital Los Angeles / University of Southern California, has more than 40 years of experience in Pathology and Laboratory Medicine. As the Director of the CPM, Dr. Triche coordinates, supports, and expands the hospital’s basic and translational research objectives in genomics, proteomics, bioinformatics, molecular genetics, molecular microbiology and cytogenetics. Dr. Triche formerly held the position of director of Specialized Diagnostics, Pathology, at the National Institutes of Health and section chief in the Laboratory of Pathology at the National Cancer Institute of the National Institutes of Health, from 1975 to 1988.
Dr. Triche has authored over 188 peer-reviewed publications, 176 abstracts and 39 book chapters and his research has been funded by major organizations such as the National Cancer Institute, the Whittier Foundation, the Department of Energy, and the Department of Defense.
About Los Angeles Syndicate of Technology – www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST’s mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.
About Sanguine BioSciences, Inc. – sanguinebio.com
Sanguine BioSciences, Inc. (“Sanguine”) is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers’ needs in the In Vitro Research & Development stage of Drug Development. Sanguine’s vision is to develop into the global leader in high quality cells and tissues for life science research and development.
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company’s ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company’s financial results can be found in the Company’s reports filed with the Securities and Exchange Commission.